Virtual Fall Conference Series
Saturday, October 16, 2021
Welcome & Introductions
Speaker: Mujahid Rizvi, MD, MPH, FACP-Hematology Oncology Associates PC, Medford OR OSMO President
Making Sense of All the Treatment Options for AML
Speaker: Elie Traer, M.D., Ph.D.
In the past 4 years, 9 new drugs have been FDA-approved for AML! Treatment has become significantly more complicated than just 7+3 or hypomethylating agent. The aim of this talk will be to understand genetic testing in AML, when to use new drugs, how to manage aza + ven, sequencing of therapy, and important side effects to be aware of.
The Now & Future of Oncology Payment Reform: Medicare Policy, 340B & More
Speaker: Ted Okon, MBA Executive Director, Community Oncology Alliance
Clinical Application of Gene Editing- Can CRISPR Cure Cancer?
Speaker: Eric Jonasch, MD
The ability to edit the genome was recently revolutionized by the discovery of the CRISPR-Cas9 gene editing system in bacteria. The translation of this technology into laboratory, human cell-line based applications was rapid, and clinical applications are being considered. This talk will summarize the technology, current use, future opportunities, and challenges facing the field of gene editing.
Please Visit with our Corporate Sponsors over at the Exhibit Hall
Live Chat Rooms will be open during this time. Please feel free to visit the virtual ‘exhibit hall’ at any time today through Friday October 22, 2021 at 6:00pm. We have over 30 exhibitors with lots of valuable resources and contact information for each company
Speakers - October 16, 2021
Mujahid Rizvi, MD, MPH, FACP
Hematology Oncology Associates PC, Medford OR OSMO President
Elie Traer, M.D., Ph.D.Dr. Traer is an associate professor of medicine at Oregon Health & Science University (OHSU). He received his M.D./Ph.D. from the University of Texas Southwestern Medical School, followed by residency in internal medicine and fellowship in hematology/oncology at OHSU. Dr. Traer’s clinical focus is on myeloid malignancies at OHSU Knight Cancer Institute, and he is involved in numerous clinical trials evaluating targeted therapy in leukemia patients. As a physician scientist, he studies how the bone marrow microenvironment provides sanctuary to leukemia cells through critical survival signals, which eventually leads to disease resistance and relapse
Ted Okon, MBA
Executive Director, Community Oncology Alliance
Eric Jonasch, MD
Eric Jonasch, MD is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Center at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. He held his clinical residency in internal medicine at the Royal Victoria Hospital in Montreal, Canada, his clinical fellowship in hematology/oncology at the New England Medical Center in Boston, Massachusetts, and his research fellowship at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. He was on faculty at the Massachusetts General Hospital for three years before moving to MD Anderson Cancer Center in Houston.
Dr. Jonasch is director of the VHL Clinical Center at the MD Anderson Cancer Center, co-Director of the MD Anderson Kidney Cancer Research Program, and is involved in tissue-based translational research in renal cell carcinoma and VHL disease. He heads a number of investigator-initiated clinical trials and is PI of the Department of Defense Kidney Cancer Research Consortium. Dr. Jonasch is in charge on an ongoing laboratory research effort evaluating the determinants of response and resistance to therapy in renal cell carcinoma and VHL disease. Dr. Jonasch’s current work focuses on understanding the drivers of renal cell carcinoma tumor ontogeny, and the development of informative models of tumor-microenvironmental interaction.
Dr. Jonasch is author or co-author of over 220 articles published in peer-reviewed journals, numerous book chapters, and editor of a textbook: Kidney Cancer, Principles and Practice. Dr. Jonasch is a journal reviewer for the New England Journal of Medicine, the Journal of Clinical Oncology, the Journal of Clinical Investigation and Cancer Research.
Dr. Jonasch is a member of multiple professional organizations, including, but not limited to the American Association for Cancer Research and the American Association of Cancer Research. Dr. Jonasch serves as Vice-Chair of the NCCN Kidney Cancer Guideline Panel and is a Board member of the International Kidney Cancer Coalition.